{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:13:19Z","timestamp":1794690799050,"version":"4.9.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>VA-ECMO is commonly used for patients in cardiogenic shock (CS) or refractory cardiac arrest (CA) undergoing PCI for ACS. In this setting at high risk of both thrombotic and hemorrhagic complications, optimal anti-thrombotic therapy remains ill-defined. We hypothesized that an anti-thrombotic therapy comprising a parenteral anticoagulant (bivalirudin) and a parenteral anti-platelet agent (cangrelor) may prove safe and effective in this scenario. From November 2019 to December 2021, 14 patients received at least one dose of cangrelor (starting dose: 0.125 \u03bcg\/kg\/min) plus bivalirudin, without background aspirin, in the context of PCI and VA-ECMO for ACS-related CS\/CA, and were included in this study. Efficacy endpoint was occurrence of thrombotic events and safety endpoint was major bleeding occurrence. Median age was 58 years. The majority (64%) presented with refractory CA. A thrombotic event occurred in 14%, while major bleeding occurred in 21% patients. One patient experienced arterial thrombosis after VA-ECMO arterial cannula removal, another experienced ischemic cerebellar stroke without functional sequelae. Bleeding events were: 29% BARC 3a, 14% BARC 3b, and 7% BARC 5b. Overall in-hospital mortality was 50%. Cangrelor was continued for 5 (4\u201310) days; temporary discontinuation was necessary in 36%, either for VA-ECMO cannula removal or for bleeding events. A low dose of cangrelor, associated with standard-intensity anticoagulation with bivalirudin was a feasible anti-thrombotic strategy in patients undergoing PCI during VA-ECMO support for ACS-related CS\/CA. Bleeding events rates outweighed thrombotic events rates in this critically-ill population, although the observed rates were lowest among available studies.<\/jats:p>","DOI":"10.1097\/mat.0000000000001871","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T20:00:20Z","timestamp":1670616020000},"page":"e346-e350","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Anti-thrombotic Therapy With Cangrelor and Bivalirudin in Venoarterial Extracorporeal Membrane Oxygenation Patients Undergoing Percutaneous Coronary Intervention: A Single-Center Experience"],"prefix":"10.1097","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5986-049X","authenticated-orcid":false,"given":"Luca","family":"Baldetti","sequence":"first","affiliation":[{"name":"Cardiac Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Nardelli","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ajello","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Melisurgo","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Calabr\u00f2","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pieri","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mara","family":"Scandroglio","sequence":"additional","affiliation":[{"name":"Cardiac Surgery Intensive Care Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"R1-20250530","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2018.11.038","article-title":"Venoarterial ECMO for adults: JACC scientific expert panel.","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250530","first-page":"44: 339\u2013340, 2020","article-title":"Use of cangrelor during venoarterial extracorporeal membrane oxygenation following percutaneous coronary intervention.","author":"Ciolek","journal-title":"Artif Organs"},{"key":"R3-20250530","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.resuscitation.2014.02.004","article-title":"High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest.","volume":"85","author":"Ibrahim","year":"2014","journal-title":"Resuscitation"},{"key":"R4-20250530","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.resuscitation.2018.06.032","article-title":"Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention.","volume":"130","author":"Fiore","year":"2018","journal-title":"Resuscitation"},{"key":"R5-20250530","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: A direct, parenteral P2Y12 receptor antagonist.","volume":"50","author":"Akers","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R6-20250530","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.athoracsur.2019.08.040","article-title":"Venoarterial ECMO without routine systemic anticoagulation decreases adverse events.","volume":"109","author":"Wood","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"R7-20250530","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.jacc.2018.02.075","article-title":"Arterial pulsatility and circulating von willebrand factor in patients on mechanical circulatory support.","volume":"71","author":"Vincent","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R8-20250530","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1111\/jth.13497","article-title":"Mechanical circulatory support is associated with loss of platelet receptors glycoprotein Ib\u03b1 and glycoprotein VI.","volume":"14","author":"Lukito","year":"2016","journal-title":"J Thromb Haemost"},{"key":"R9-20250530","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-0034-1383817","article-title":"Multiple electrode aggregometry for the assessment of acquired platelet dysfunctions during extracorporeal circulation.","volume":"63","author":"Mutlak","year":"2014","journal-title":"Thorac Cardiovasc Surg"},{"key":"R10-20250530","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2020.02.004","article-title":"Strategies of left ventricular unloading during VA-ECMO support: A network meta-analysis.","volume":"312","author":"Baldetti","year":"2020","journal-title":"Int J Cardiol"},{"key":"R11-20250530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: A randomized controlled trial.","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"R12-20250530","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y 12 inhibition from the IABP-SHOCK II trial.","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"key":"R13-20250530","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1053\/j.jvca.2017.03.028","article-title":"Maintenance of drug-eluting stent patency through use of a cangrelor infusion in the clinical setting of massive pulmonary hemorrhage and venoarterial extracorporeal membrane oxygenation.","volume":"31","author":"Seelhammer","year":"2017","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R14-20250530","first-page":"10: 1712","article-title":"Cangrelor use in cardiogenic shock: A single-center real-world experience.","author":"Vaduganathan","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"R15-20250530","first-page":"1222","article-title":"Clinical use of cangrelor after percutaneous coronary intervention in patients requiring mechanical circulatory support.","volume":"2021","author":"Katz","year":"1215","journal-title":"Ann Pharmacother"},{"key":"R16-20250530","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1060028018795840","article-title":"Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.","volume":"53","author":"Bowman","year":"2019","journal-title":"Ann Pharmacother"},{"key":"R17-20250530","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCINTERVENTIONS.110.959098","article-title":"Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.","volume":"4","author":"Kimmelstiel","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"R18-20250530","doi-asserted-by":"crossref","first-page":"E998","DOI":"10.25270\/jic\/21.00013","article-title":"Safety of intravenous cangrelor administration for antiplatelet bridging in hospitalized patients: A retrospective study.","volume":"33","author":"Johnson","year":"2021","journal-title":"J Invasive Cardiol"}],"container-title":["ASAIO Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000001871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:06:51Z","timestamp":1748610411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MAT.0000000000001871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mat.0000000000001871","relation":{},"ISSN":["1058-2916"],"issn-type":[{"value":"1058-2916","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,8]]}}}